Biomea Fusion, Inc. (BMEA) Stock

Biomea Fusion, Inc. (BMEA) is a Healthcare stock trading at $1.36 (as of 2026-08-21), with a market capitalization of $98.58M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Biomea Fusion, Inc. is a biopharmaceutical company developing covalent small-molecule drugs for genetically defined cancers and metabolic diseases. Its pipeline includes BMF-219, an orally available covalent inhibitor of menin.

Valuation — source: SEC EDGAR (first-party)
Price$1.36
Market Cap$98.58M
Price / Book8.12
FCF Yield-57.2%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($13.48M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael J. Hitchcock
Employees79
CountryUS
IPO Date2021-04-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Rafael Holdings, Inc. (RFL)
  • Polaryx Therapeutics, Inc. Common Stock (PLYX)
  • Fortress Biotech, Inc. (FBIO)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Aldeyra Therapeutics, Inc. (ALDX)
  • Rallybio Corporation (RLYB)
  • Gain Therapeutics, Inc. (GANX)
  • Adicet Bio, Inc. (ACET)
BMEA earnings history · BMEA institutional & insider holders · BMEA KPIs & operating metrics · BMEA financials · BMEA investor presentations & press releases · BMEA SEC filings · BMEA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.